microRNA and Oxidative Drugs in Cancer Therapy and Prevention

Dear Colleagues,

The epigenetic control of gene expression is achieved at the postgenomic level in the cytoplasm by microRNA machinery. MicroRNAs are able to intercept and suppress messenger RNAs encoded by mutated oncogenes, thus blocking the progress, spreading, and recurrences of cancer. Indeed, cancer growth occurs only when microRNA machinery is severely damaged. MicroRNA expression can be restored and modulated by the administration of suitable microRNA mimics. This approach is particularly important in cancer stem cells characterized by a peculiar micoRNA profile, quiescent status, and a high abundancy of antioxidants, making these cells resistant to chemo-radiotherapies. In this context, oxidative drugs and inhibition of Nrf2 antioxidant pathways may be proposed as possible strategies to target cancer stem cell and to decrease the probability of cancer relapse.

The goal of this Special Issue is to focus on the clinical applicability of microRNA and oxidative drugs to cancer therapy and prevention. The issue will analyze the status of experimental knowledge in preclinical experimental models as well as the translatability of the obtained results to the clinics. Attention will be focused on advantages and problems limiting the feasibility of applying these new strategies in human patients. Attention will be focused on the use of microRNA and oxidative drugs as complimentary approaches to chemo-radiotherapies in cancer therapy to overcome resistance and in cancer prevention to decrease the risk of relapses. 

Prof. Dr. Alberto Izzotti
Prof. Dr. Ming You
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.